BACKGROUND AND PURPOSE: Future demographic changes predict an increase in the number of patients with atrial fibrillation. As long-term anticoagulation for the prevention of ischemic strokes becomes more prevalent, the burden of warfarin-associated intracerebral hemorrhage (W-ICH) is likely to grow. However, little is known about the clinical aspects and pathophysiologic mechanisms of W-ICH. This study describes the development of a mouse model of W-ICH in which hematoma growth and outcomes can be correlated with anticoagulation parameters. METHODS: CD-1 mice were treated with warfarin (2 mg/kg per 24 hours) added to drinking water. ICH was induced by stereotactic injection of collagenase type VII (0.075 U) into the right striatum. Hemorrhagic blood volume was quantified by means of a photometric hemoglobin assay 2 and 24 hours after hemorrhage induction. Neurologic outcomes were assessed on a 5-point scale. RESULTS: The international normalized ratio in nonanticoagulated mice was 0.8+/-0.1. After 24 (W-24) and 30 (W-30) hours of warfarin pretreatment, international normalized ratio values increased to 3.5+/-0.9 and 7.2+/-3.4, respectively. Compared with nonanticoagulated mice, mean hemorrhagic blood volume determined 24 hours after hemorrhage induction was found to be 2.5-fold larger in W-24 mice (P=0.019) and 3.1-fold larger in W-30 mice (P<0.001, n=10 per group). Mortality at 24 hours after hemorrhage induction was 0% in nonanticoagulated mice, 10% in W-24 mice, and 30% in W-30 mice. Hematoma enlargement between 2 and 24 hours after hemorrhage induction was -1.4% for nonanticoagulated mice, 22.9% for W-24 mice, and 62.2% for W-30 mice. CONCLUSIONS: This study characterizes the first experimental model of W-ICH. It may be helpful in gaining further insights into the pathophysiology of W-ICH and may be used for testing the efficacy of treatment strategies, such as hemostatic therapy, in this severe subtype of stroke.
BACKGROUND AND PURPOSE: Future demographic changes predict an increase in the number of patients with atrial fibrillation. As long-term anticoagulation for the prevention of ischemic strokes becomes more prevalent, the burden of warfarin-associated intracerebral hemorrhage (W-ICH) is likely to grow. However, little is known about the clinical aspects and pathophysiologic mechanisms of W-ICH. This study describes the development of a mouse model of W-ICH in which hematoma growth and outcomes can be correlated with anticoagulation parameters. METHODS:CD-1mice were treated with warfarin (2 mg/kg per 24 hours) added to drinking water. ICH was induced by stereotactic injection of collagenase type VII (0.075 U) into the right striatum. Hemorrhagic blood volume was quantified by means of a photometric hemoglobin assay 2 and 24 hours after hemorrhage induction. Neurologic outcomes were assessed on a 5-point scale. RESULTS: The international normalized ratio in nonanticoagulated mice was 0.8+/-0.1. After 24 (W-24) and 30 (W-30) hours of warfarin pretreatment, international normalized ratio values increased to 3.5+/-0.9 and 7.2+/-3.4, respectively. Compared with nonanticoagulated mice, mean hemorrhagic blood volume determined 24 hours after hemorrhage induction was found to be 2.5-fold larger in W-24 mice (P=0.019) and 3.1-fold larger in W-30 mice (P<0.001, n=10 per group). Mortality at 24 hours after hemorrhage induction was 0% in nonanticoagulated mice, 10% in W-24 mice, and 30% in W-30 mice. Hematoma enlargement between 2 and 24 hours after hemorrhage induction was -1.4% for nonanticoagulated mice, 22.9% for W-24 mice, and 62.2% for W-30 mice. CONCLUSIONS: This study characterizes the first experimental model of W-ICH. It may be helpful in gaining further insights into the pathophysiology of W-ICH and may be used for testing the efficacy of treatment strategies, such as hemostatic therapy, in this severe subtype of stroke.
Authors: L Sjöblom; H G Hårdemark; A Lindgren; B Norrving; M Fahlén; M Samuelsson; L Stigendal; D Stockelberg; A Taghavi; L Wallrup; J Wallvik Journal: Stroke Date: 2001-11 Impact factor: 7.914
Authors: Maria I Aguilar; Robert G Hart; Carlos S Kase; William D Freeman; Barbara J Hoeben; Rosa C García; Jack E Ansell; Stephan A Mayer; Bo Norrving; Jonathan Rosand; Thorsten Steiner; Eelco F M Wijdicks; Takenori Yamaguchi; Masahiro Yasaka Journal: Mayo Clin Proc Date: 2007-01 Impact factor: 7.616
Authors: Nils Kucher; Luis R Castellanos; Rene Quiroz; Sophia Koo; John Fanikos; Samuel Z Goldhaber Journal: Am J Cardiol Date: 2004-08-01 Impact factor: 2.778
Authors: Joshua M Levine; Ryan Snider; David Finkelstein; Mahmut E Gurol; Rishi Chanderraj; Eric E Smith; Steven M Greenberg; Jonathan Rosand Journal: Neurocrit Care Date: 2007 Impact factor: 3.210
Authors: Tim Lekic; Robert P Ostrowski; Hidenori Suzuki; Anatol Manaenko; William Rolland; Nancy Fathali; Jiping Tang; John H Zhang Journal: Acta Neurochir Suppl Date: 2011
Authors: Arne Lauer; Flor A Cianchetti; Elizabeth M Van Cott; Frieder Schlunk; Elena Schulz; Waltraud Pfeilschifter; Helmuth Steinmetz; Chris B Schaffer; Eng H Lo; Christian Foerch Journal: Circulation Date: 2011-09-12 Impact factor: 29.690
Authors: Opeolu Adeoye; Joseph F Clark; Pooja Khatri; Kenneth R Wagner; Mario Zuccarello; Gail J Pyne-Geithman Journal: Transl Stroke Res Date: 2010-08-10 Impact factor: 6.829
Authors: Anton Pekcec; Kazim Yigitkanli; Joo Eun Jung; Stefanie Pallast; Changhong Xing; Alexander Antipenko; Maria Minchenko; Dimitar B Nikolov; Theodore R Holman; Eng H Lo; Klaus van Leyen Journal: FASEB J Date: 2012-10-15 Impact factor: 5.191